Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allarity Therapeutics, Inc. (NASDAQ: ALLR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Phase 2 clinical-stage biopharmaceutical company focused on stenoparib and its DRP® companion diagnostic platform, Allarity uses SEC reports to communicate material events, financing transactions, and periodic financial information to investors.
Among the key documents available are Form 8-K current reports, where Allarity has disclosed events such as FDA Fast Track designation for stenoparib in advanced ovarian cancer, new clinical data presentations from its Phase 2 ovarian cancer trial, conference participation on biomarkers and precision medicine, licensing and laboratory services agreements for DRP® algorithms, and private placement securities purchase agreements. Filings like NT 10-Q (Form 12b-25) explain timing of quarterly reports and provide context on the status of financial statement reviews.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping users quickly understand disclosures related to clinical development, capital structure, registration rights, and governance changes. Real-time updates from EDGAR ensure that new Allarity filings are added as they become available, including quarterly and annual reports when filed, as well as any future Forms 10-K, 10-Q, or additional 8-Ks.
Investors researching ALLR can use this page to review how Allarity describes its business focus on stenoparib and DRP®, track unregistered equity offerings and registration rights agreements, and monitor other material events reported under SEC rules. The combination of original documents and AI-generated overviews is intended to make complex regulatory language more accessible while preserving the underlying source information.
Allarity Therapeutics has formally requested the withdrawal of its Form S-3 registration statement (File No. 333-281864) filed on August 30, 2024. The company has decided not to proceed with the planned public offering at this time.
Key points from the withdrawal request:
- The registration statement was never declared effective by the SEC
- No securities were issued or sold under this registration
- The company acknowledges no refund will be made for filing fees
- Allarity requests that paid fees be credited to offset future registration statement costs under Rule 457(p)
The withdrawal request, submitted by CEO Thomas H. Jensen on June 24, 2025, is made pursuant to Rule 477 under the Securities Act of 1933. This action indicates a significant shift in the company's capital raising strategy and could impact its near-term financing plans.